BMY vs MDT

Bristol-Myers Squibb's Advanced Deterministic Scorecard shows a Piotroski F-Score of 4/9, indicating stable but not strong financial health, while the absence of an Altman Z-Score prevents a definitive distress risk assessment. The stock trades below its growth-based intrinsic value of $87.32 at $54.65, suggesting potential undervaluation, yet the high debt/equity ratio and inconsistent earnings performance temper optimism. Strong profitability metrics like 31.57% operating margin and 33.78% ROE are offset by weak recent earnings growth and bearish insider activity. Analysts consensus is a hold with a $56.96 target, implying limited upside, while the 4.59% dividend yield offers income appeal despite an elevated 83.5% payout ratio.

Medtronic exhibits a stable but uninspiring financial profile, evidenced by a Piotroski F-Score of 4/9. While the company maintains a strong balance sheet with a Current Ratio of 2.54 and low Debt/Equity (0.57), it is currently facing a severe technical downtrend and negative earnings growth (-11.8% YoY). There is a significant valuation gap, as the current price of $79.37 trades well above the Graham Number ($55.45) and the growth-based Intrinsic Value ($25.06). The divergence between bullish analyst targets ($108) and bearish insider activity/price action suggests a period of high uncertainty.